Research synthesisLow evidenceModerate effect3 studies · 2 beneficial · 1 neutral · 0 harmful
Across 3 studies, 2 reported beneficial effects of vitamin B2 (riboflavin) on reducing migraine duration, with effect sizes ranging from moderate in a 2022 meta-analysis (400 mg/day, 90 days) to mixed in a 2026 review (up to 400 mg/day), while a large 2024 pediatric meta-analysis found no significant benefit. The most-studied dose is 400 mg/day, and effects were typically observed over 90 days. Overall, evidence is mixed, with beneficial findings limited to adult populations and no effect seen in pediatric patients.
- Effective dose range: 400 mg/day
- Studied populations: adults with migraine (general clinical population)
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. The largest and highest-quality study (pediatric meta-analysis, n=3771, evidence score 8) found no significant reduction in migraine duration, contrasting with two smaller meta-analyses in mixed/adult populations. Effect sizes varied; the 2026 review reported high heterogeneity (I² = 90.4%), suggesting inconsistent results across trials.
Generated Jul 12, 2026